Abstract Inflammatory bowel disease (IBD) constitutes an important clinically significant condition that results in morbidity and mortality. IBD can be generally classified into either ulcerative colitis (UC) or Crohn's disease (CD) that differs in the clinical and histopathology. The role of neuropeptides in the pathogenesis of these conditions is becoming increasingly recognized for their importance in modulating the inflammatory state. Animal models provide the greatest insight to better understand the pathophysiology of both disorders which will hopefully allow for improved treatment strategies. This review will provide a better understanding of the role of murine models for studying colitis.
IBD and Mouse Models of Colitis
Inflammatory bowel disease (IBD) is a gastrointestinal disorder that includes ulcerative colitis (UC) and Crohn's disease (CD) (Abraham and Cho 2009) . Studies have shown that IBD is a multifactorial set of diseases that result from an unregulated inflammatory response to intestinal microbes and foreign antigens in genetically susceptible hosts (Nielsen and Ainsworth 2013) . Patients with IBD develop intestinal inflammation that often manifests as abdominal pain, bloody diarrhea, fevers, and weight loss. Histologically, the inflamed intestinal mucosa of IBD patients shows immune cell infiltration, bowel wall edema, loss of goblet cells, ulcer formation, and diffuse erosions. For CD, these inflammatory lesions typically involve the whole intestinal wall and can occur throughout the entire gastrointestinal tract. UC, on the other hand, is restricted to the colon and rectum, and the inflammatory changes seen in tissue specimens are typically limited to the mucosal layer (Abraham and Cho 2009) . Research has shown that the key factors implicated in IBD pathogenesis include tumor necrosis factor alpha (TNF-α), . Therapies directed against these cytokines have been partially successful in treating aspects of IBD (Targan et al. 1997; Sandborn et al. 2008) . However, up to 40 % of CD patients do not have a clinically relevant response to TNF-α inhibitors, but for UC patient, it may be as high as 50 %. Additionally, during 12 months of continuous treatment, two thirds of CD patients do not have a sustained clinical response to the treatment (Nielsen and Ainsworth 2013; Rutgeerts et al. 2005) . Given the significant morbidity associated with IBD, researchers are working on unraveling the pathogenesis of the disease with the hope of identifying new and effective therapies. One important tool in deciphering the pathogenesis of IBD has been the research use of animal models of colitis in which new pathogenic hypotheses can be tested and new therapeutics can be investigated.
Several varieties of mouse models of colitis have been generated to investigate the etiology of intestinal mucosa inflammatory diseases. These models can be categorized into four broad groups: genetically engineered, immune manipulated, spontaneous and erosive/chemically induced models. Each mouse model possesses unique strengths and weaknesses in the study of intestinal inflammatory diseases with no mouse model completely replicating the characteristic IBD clinical pathology. Prior to 1993, most animal models relied on chemical induction of inflammation, originally described in the 1950s and 1960s (Kirsner and Elchlepp 1957; Kirsner et al. 1959; Kraft et al. 1963) . However, in 1993, several studies were published showing colitis models in genetically engineered mice in the absence of exogenous chemicals or erosive agents (Mombaerts et al. 1993; Sadlack et al. 1993; Powrie et al. 1993) . Over the past several decades, these mouse models have helped to reveal important details regarding the biology of intestinal inflammation.
Chemically Induced Mouse Models of Colitis
Dextran sulfate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) models of colitis in mice are among the most commonly used models to study intestinal inflammation. The ease of application and the relatively low cost make these models ideal for studying a vast array of inflammatory processes.
The use of DSS dates back to 1985 with the publication of a hamster model to study UC (Ohkusa et al. 1985) . DSS is a sulfated polysaccharide shown to induce acute, self-limiting colitis in multiple models including hamsters, rats, guinea pigs, and mice (Obata et al. 1994; Iwanaga et al. 1994) . Animals that are given DSS in their drinking water develop intestinal inflammation. Typically, they are given concentrations of 2-10 % of DSS for brief time periods of 4-14 days (Kitajima et al. 2001) . The severity of colitis differs with the administration of different molecular weights of DSS such as 5, 40, and 500 kDa (Perse and Cerar 2012) . This variable response may be dependent on factors related to the DSS concentration, molecular weight, duration of DSS exposure, and chemical batch, but they are related also to animal strain differences and colonic bacterial microflora. Interestingly, the DSS-induced inflammation does not appear to require the presence of T cells or B cells and can even be induced in immunodeficient animals (Dieleman et al. 1994; Krieglstein et al. 2002) . Mouse strains have shown different genetic susceptibilities to DSS-induced colitis in various studies, as Swiss Webster, C3H/HeJ are the most susceptible to DSS colitis (Jones-Hall and Grisham 2014), whereas, NOD/LtJ are more resistant. Melgar et al. described that, in 5-days of exposure to DSS, C57BL/6 mice developed progressive chronic colitis, whereas BALB/c mice only had an acute colitis which completely resolved after DSS removal (Melgar et al. 2005) .
The first changes related to DSS were observed after 1 day of DSS treatment and include the loss of tight junction complex and increased pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ, IL-10, and IL-12) in the colon (Kitajima et al. 1999) . The earliest histologic lesions observed in DSSinduced colitis are typically seen at day 3. At this time point, histology reveals loss of crypts, ulcerations, and erosions, whereas, in the following days, mucosal edema, epithelial degradation, loss of goblet cells, mucin depletion, abscesses, and infiltration of neutrophils, macrophages, lymphocytes and plasma cells become recognizable (Cooper et al. 1993) . On a macroscopic level, the DSS colitis model can induce weight loss, bloody diarrhea, anemia, and eventually death.
The mechanisms of action for DSS are thought to be direct toxicity to colonic epithelial cells and alteration of the epithelial barrier integrity. The DSS model is a model of injuryinduced necrosis and inflammation rather than a lymphocyte-driven model of chronic disease. Additionally, an imbalance between epithelial apoptosis and proliferation has seen suggested to be implicated as an important factor in the pathogenesis of the enteric lesions (Araki et al. 2010) . As a result, colonic mucosal permeability increases and enables the penetration of large molecules as DSS. However, the manner in which DSS passes through the mucosal epithelial cell layers and induces colitis remains unclear. One hypothesis is that DSS-induced epithelial barrier dysfunction may allow the entry of luminal antigens and microorganisms into the mucosa resulting in a break of oral tolerance and an immune inflammatory response (Perse and Cerar 2012) .
One of the advantages of DSS-induced mouse colitis model is that the histologic alterations are similar to the features of IBD in humans. As human UC, DSS colitis shows a rectal localization and marked mucosal ulcerations and edema. However, DSS colitis can also occasionally exhibit features of CD such as transmural inflammation, patchy distribution of inflammation, prominent lymphoid follicles, and fissuring ulcers (Perse and Cerar 2012) . The cytokine profile for DSS colitis shows the involvement of Th1, Th2, and Th17 cytokine pathways (Dieleman et al. 1994) . Additionally, this model can develop dysplastic lesions that resemble those observed in human UC. Furthermore, DSS-induced colitis is considered an acceptable model that can be used for translational studies investigating various therapeutic agents to treat human IBD (Perse and Cerar 2012) . However, the lack of a definitive role for the adaptive immune system and the intestinal microbiota in the pathogenesis of colitis has suggested that the DSS model might be more useful in investigating the mechanisms of mucosal wound repair rather than true colitis (Koboziev et al. 2011 ).
The intrarectal administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS) induces an erosive colitis. It was first used in rats and gained popularity with the use of this model to mice over the past 10-15 years (Fiorentino et al. 1991; Wirtz et al. 2007 ). Neurath et al. first described this procedure for inducing colitis in 2-4 months old BALB/c or SJL/J mice (Neurath et al. 1995) . The mechanism of action is thought to be through the ethanol disruption of the mucosal barrier that enables the translocation of the water soluble TNBS into the submucosal layer. TNBS, which is a hapten, is hypothesized to interact with some amino acid groups on intestinal mucosa and bacterial proteins, in such a way inducing a delayed-type hypersensitivity reaction (Jones-Hall and Grisham 2014). TNBS-treated animals develop diarrhea, rectal bleeding, rectal prolapse, and marked wasting. The clinical manifestations typically peak by 2-4 weeks and can be followed by partial recovery or death. Histologically, there are significant transmural immune inflammatory infiltrates, composed of macrophages, CD4 lymphocytes, and neutrophils. Ulceration, edema, and loss of goblet cells can be seen by day 7. However, even at a 2-month time point, lymphoid aggregates were still present, and early fibrosis can be detected (Neurath et al. 1995) .
The TNBS model has a characteristic cytokine profile consistent with Th1 and Th17 cells. Isolated lamina propria CD4+ T cells have been shown to produce high levels of IL-12, IL-17, TNF-α, IFN-gamma, IL-2, macrophage inhibitory protein-1, and lower levels of IL-4 (Alex et al. 2009 ). Of note, one study showed that the severity of TNBS-induced colitis can be decreased by antibodies to anti-IL-12 (Neurath et al. 1995) . In TNBS chronic models of inflammation, continued increases of IL-12, IL-17, and macrophage inhibitory protein-1 were found, thus suggesting the existence of an increased Th1/Th17 response, more consistent with a CD pathogenesis (Alex et al. 2009 ). As in the DSS colitis models, different strains of mice have variable degrees of inflammation in the TNBS model as the SJL/J and BALB/c mice are highly susceptible, whereas, C57BL/6 and C57BL/10 mice are more resistant to its development (Jones-Hall and Grisham 2014). Ultimately, the TNBS model has the advantage of being simple to use, inexpensive and relatively reproducible, while it mimics the CD pathophysiology.
Early Genetically Engineered Mouse Models
As noted, the genetically modified animal models of colitis have greatly expanded our understanding of gastrointestinal inflammation. One of the first models was the IL-10 knockout murine model. IL-10 was initially identified as a cytokine produced by T helper cell subset 2 (Th2) that would inhibit the activity of Th1 cells (Fiorentino et al. 1989 ). For example, in vitro studies found that IL-10 can suppress Th1 cytokine profile and growth of various inflammatory immune cells (Go et al. 1990 ). Defective IL-10 signaling pathway genes were found to be involved in both CD and UC, indicating that an impaired IL10 signaling is likely to be involved in the development of gastrointestinal inflammation (Glocker et al. 2009; Begue et al. 2011; Shah et al. 2012 ). In 1993, Kuhn et al. published the first description of the IL-10 knockout mouse model and showed that IL10-/-mice raised in conventional housing environments are predisposed to developing spontaneous enterocolitis by 2-3 months of age (Kuhn et al. 1993) . The lack of evidence of intestinal inflammation in neonates suggests that the colitis is likely the result of an inappropriate response to enteric antigens (Dieleman et al. 1994) . Of note, IL-10 knockout mice raised in a germ-free environment did not develop colitis (Berg et al. 1996; Sellon et al. 1998) . Histologically, at 3 months, the IL-10 knockout mice show multifocal lesions throughout the cecum, colon, and rectum with much fewer lesions being present in the small bowel (Rennick et al. 1997) . The inflammatory infiltrates were present in the mucosa and submucosa and were notable for epithelial hyperplasia, crypt abscesses, and focal ulcers. By 6 months, the lesions became more severe, and the majority of animals developed colorectal adenocarcinomas (Rennick et al. 1997) . Clinically, the mice developed weight loss, leukocytosis, splenomegaly, and anemia. The mice were found to have higher levels of IL-1, IL-6, tumor necrosis factor-alpha, and interferon-gamma (Berg et al. 1996) . The IL10-/-murine model continues to be a powerful tool in the study of gastrointestinal inflammation.
A second genetically modified animal model was published a few years later targeting the gene for the G protein subunit Gai2 (Hornquist et al. 1997) . Deletion of this gene led to the development of a mucosal inflammatory process that is clinically and pathologically similar to ulcerative colitis in humans. These animals showed acute and chronic mucosal inflammation with ulcerations limited to the colon as well as the development of crypt abscesses and loss of goblet cells. Gai2 knockout mice have irregular dilatation of the colon that presented focal lesions with thickened and inflamed wall. Interestingly, one third of these knockout animals developed invasive, nonpolypoid adenocarcinomas as early as 12 weeks of age. Mechanistically, thymocytes and peripheral T cells from Gia2 knockout animals produced substantially more IL-2, IFN-gamma, and TNF-α (Hornquist et al. 1997) .
Additional mouse models that have been critical in expanding our understanding of inflammatory bowel disease include the adoptive T cell models. One particularly troublesome aspect of working on IL10 knockout and other genetically engineered models is that the time to inflammation as well as the severity of inflammation is highly variable. In the adoptive T cell models, naïve (CD4+CD45RBhigh) T cells are transferred into immunodeficient animals and can induce reliable degrees of inflammation within the gut (Powrie et al. 1993; Ostanin et al. 2006) . One of the main immunodeficient mice used are the recombinase-activating gene-1-deficient (RAG-/-) mice. Adoptive T cell transfers into these animals can induce pancolitis including small bowel inflammation at 6-8 weeks, a feature that is unique among the various mouse models of IBD (Ostanin et al. 2006) . Histological evaluation of the intestines shows hallmarks of CD pathophysiology such as transmural inflammation, epithelial cell hyperplasia, mononuclear infiltration, and villous blunting. In the more severe cases, there were also loss of crypts to inflammatory infiltrates and the formation of crypt abscesses (Izcue et al. 2006 ).
Neuropeptides Regulating Immune Function in the GI Tract
Neuropeptides such as substance P (SP), neurotensin, neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP), and somatostatin are important signaling mediators that connect the nervous system to a variety of cell types within the intestines. Both immune and non-immune cells express neuropeptide receptors and have been shown to regulate a network of genes implicated in immune regulatory processes. Studies have revealed that neuropeptides are implicated in the interaction between epithelial and immune cells to initiate and maintain inflammation. Neuropeptides can modulate the innate immune response by affecting phagocytosis, release of oxygen and nitrogen radicals, and the production of pro-and antiinflammatory molecules. They are typically synthesized as precursors and then packaged and processed to mature neuropeptides within the secretory granules (Hoyer and Bartfai 2012) . Their role in the development of colitis, however, has yet to be fully characterized. This review will highlight some of the studies aimed at identifying the role of neuropeptides in the development of IBD.
Neurotensin and Colitis
Neurotensin is a 13 amino acid bioactive peptide mainly expressed in the brain and gastrointestinal tract (Carraway and Leeman 1976) . Within the GI tract, it has been shown via immunohistochemistry to be localized into endocrine cells and neurons of the mucosa, submucosa, and muscularis layers. In addition to its actions in the brain, neurotensin acts on the cardiovascular, gastrointestinal, and central nervous systems, particularly on chloride secretion, cellular motility, and cell growth. In the intestine, neurotensin has trophic effects on the small and large bowel, pancreas, and stomach. It has been shown to inhibit gastric and small bowel motility while stimulating colonic motor activity. Animal studies have shown that intravenous administration of neurotensin can cause mast cell degranulation and increase in vascular permeability, histamine, and leukotrienes levels (Carraway et al. 1982 (Carraway et al. , 1991 . Neurotensin interacts on the cell surface of both immune and epithelial cells with specific receptors (NTR1 and NTR2) that belong to the seven trans-membrane G-proteinlinked superfamily (Tanaka et al. 1990; Mazella et al. 1996) . Using the TNBS colitis rat model, Akcan et al. described a reduction in inflammation in the setting of exogenous neurotensin administration. Neurotensin-treated rats have lower colitis scores and lower inflammatory cytokines, as TNF-α and IL-6 (Akcan et al. 2008) . However, additional studies, revealed an opposite effect for neurotensin in colitis. Using a Clostridium difficile toxin model of inflammation, Castagiuolo et al. showed that intestinal inflammation could be inhibited by the administration of a neurotensin receptor antagonist. Colonic explants exposed to either C. difficile toxin or neurotensin have an increase in mast cell degranulation, which could be inhibited by the neurotensin receptor inhibitor (Castagliuolo et al. 1999) . Further evidence for neurotensin as a promoter of colitis comes from studies that used genetically modified animals. Koon et al. induced TNBS colitis in neurotensin knockout mice and showed a reduced inflammatory response and lower levels of inflammatory cytokines. In this study, neurotensin signaling in mesenteric fat cells led to inflammatory cytokines secretion and macrophage infiltration (Koon et al. 2009 ). Differences in neurotensin effects in colitis might be due to the specific experimental design. However, given its increase in animal models of colitis and in IBD patients, it appears that neurotensin could actively participate in the inflammatory process (Brun et al. 2005) . Further research will be necessary to determine whether neurotensin can serve as a theraupeutic target or biomarker for IBD treatment.
Vasoactive Intestinal Polypeptide (VIP) and Colitis
The neuropeptide vasoactive intestinal peptide (VIP) is a 28 amino acid peptide originally isolated from the small intestine of pigs in 1970 (Abad et al. 2015) . VIP, initially found in the lungs and gastrointestinal tract, is often associated with neurons and nerve fibers (48). Within the gastrointestinal tract, VIP is located in all the layers of the colonic mucosa with the highest concentration in the myenteric plexus (Said and Mutt 1970; Surrenti et al. 1993) . VIP is part of the secretin and glucagon family of peptides and has a 68 % homology with the pituitary adenylyl cyclase-activating polypeptide (PACAP) neuropeptide. VIP and PACAP bind to their specific G protein-coupled receptors VPAC1 and VPAC2 (Pisegna and Oh 2007) . Through these receptors, VIP is able to perform a broad array of functions such as regulating gastric acid and intestinal secretions, enzymes release from the exocrine and endocrine pancreas, cellular motility, vasodilation, and intestinal contractility (Harmar et al. 2012; Bloom et al. 1973) . Additionally, VIP has been shown to modulate T cell and macrophage development as well as cytokine production.
VIP can regulate the Th1/Th2 balance by altering their regulatory cytokines (Sun et al. 2006; Voice et al. 2001) . Given its role in immune cell regulation, VIP has been investigated also in animal models as a potential modulator of colonic inflammation; however, the results of several studies have not been consistent. Abad et al. in 2003 , using a TNBS mouse model of colitis, reported that exogenous VIP administration reduced the clinical and histopathologic severity of the disease and mitigated weight loss, diarrhea, and intestinal inflammation (Abad et al. 2003) . However in 2005, Newman et al. using the same TNBS murine model demonstrated that prophylactic or therapeutic intraperitoneal treatment with VIP did not affect the clinical and histological inflammatory parameters (Newman et al. 2005) . More recently, the development of VIP and VPACs genetically engineered mouse models has allowed a better characterization of the endogenous VIP pathways in colitis. VIP knockout animals were described by Lelievre et al. to have altered intestinal anatomy at baseline with distorted colonic crypts, cell proliferation anomalies, increased apoptosis, and altered permeability (Lelievre et al. 2007 ). Yusta et al. also reported their findings on VIP knockout animals and showed abnormal villous structure, increases in the crypt compartment, and cell proliferation within the small bowel. Notably, these changes were not seen by antagonizing VIP in wildtype animals and surprisingly, they were not reversed by exogenous administration of VIP in the knockout animals (Yusta et al. 2012) . These results suggest that VIP has a role in early development of the gut and in certain contexts is not easily reversible.
In 2011, Yadav et al. analyzed the role of VPACs receptors using specific knockout mice and the DSSinduced colitis model. While VPAC2 receptor knockout mice on T-cells were shown to develop a worse course of DSS-induced colitis, VPAC1 knockout were seen to be resistant to colitis (Yadav et al. 2011) . Recent studies by Vu et al. (2014) , using the DSS colitis model, revealed that VIP knockout mice and wild type mice treated with a VIP or VPAC1 antagonist, became resistance to colitis and had significantly reduced levels of colonic inflammation and expression of inflammatory cytokines. In 2015, Abad et al., using the TNBS model in VIP knockout mice, showed a resistance to colitis and observed lower levels of TNF-α and IL-6 inflammatory cytokines as compared to WT littermates (Abad et al. 2015) . Finally, in 2015, Wu et al. evaluated a VIP knockout animal using dinitrobenzene sulfonic acid (DNBS) or DSS treatments and found that they developed more severe colitis. In an elegant study, the knockout animals were treated with exogenous VIP, which rescued the phenotype (Wu et al. 2015) . Overall, these seemingly controversial results highlight the complexity of VIP signaling and the context-dependent signaling that is at play in each of these models.
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and Colitis
Immunological over-responsiveness to unknown stimuli has been listed as a possible cause of IBD. The key modulators in IBD are considered the mucosal, antigen-activated T cells that have a Th1 cytokine phenotype in CD and mainly a mixed Th1/Th2 phenotype in UC (Abraham and Cho 2009) . The colonic mucosa is abundantly innervated by fibers containing neuropeptides; they are known to play an important role in the digestive motility and secretory functions, but their effects on the gut immune responses are still obscure. Pituitary adenylate cyclase-activating polypeptide (PACAP) is the last discovered neuropeptide in the VIP, secretin, and glucagon family of peptide hormones. Three types of receptors have been identified for PACAP: VPAC1 and VPAC2, that are both coupled to only adenylyl cyclase (AC), whereas the other receptor, PAC1, has a 1000-fold selectively higher affinity for PACAP and can couple to both AC and phospholipase C (PLC) (Pisegna and Wank 1996) . It was previously shown that PACAP and PAC1 are abundantly expressed in the myenteric plexus of normal colonic mucosa, and that PAC1 are expressed in normal human, rodent, and Jurkat T cells (unpublished data), in which PACAP induces cAMP increase, inhibits tyrosine phosphorylation, IL-2 release and mitosis (Miampamba et al. 2002) . Also, it was recently shown that PAC1 can enhance the T cell receptor (TCR) intracellular signaling, via Gaq and PLCγ coupling, causing Ca 2+ increase, IL-2 release and proliferation. PACAP potently regulates the immune system through the activation of PAC1 (Pozo 2003) ; however, the role of PACAP and its receptor, PAC1, in inflammatory colitis is unclear and deserves further investigation.
Discussion and Clinical Implications
Experimental models of colitis are critical in identifying new and promising therapies to tackle the course of IBD. Given the multifactorial nature of IBD's pathophysiology, researchers will continue to rely on complex model systems to understand the mechanisms behind IBD and develop better future therapies. Indeed, the development of the Smad7 antisense therapy, the latest in novel therapeutic approaches to treat IBD, has relied heavily on mouse models of colitis (Lowenberg and D'Haens 2015) . Smad7 is part of the TGF-beta signaling pathway and functions as an inhibitor which prevents the signaling to the nucleus from activated TGF-beta receptors to initiate transcription of various downstream targets (Massague 2012) . Researchers have found that IBD patients expressed high levels of TGF-beta, whose signaling pathway is known for inhibiting immune cell function (Stadnicki et al. 2009 ). This seemingly contradictory finding was explained by the finding that IBD patients also express higher levels of the inhibitory Smad7 (Monteleone et al. 2001) . The expression of high Smad7 levels inhibits the TGF-beta signaling and its immune suppressor functions. Researchers have then decreased the expression of Smad7 by using an antisense molecule (Boirivant et al. 2006 ). This novel therapeutic approach was tested in a mouse TNBS colitis model and found to efficiently restore active TGF-beta signaling and reduce TNBS-induced colitis severity (Boirivant et al. 2006) . Recently, the results of a phase 2 clinical trial that were published showed in active CD patients impressive results with a significant percentage of patients treated with Smad7 antisense therapy achieving clinical remission (Monteleone and Pallone 2015) . These results, along with many others, highlight the importance of experimental colitis models in IBD research.
As described above, neuropeptides play complex roles in immune cell regulation. Many studies highlight the contextdependent nature of neuropeptide signaling and its role in regulating the development and function of immune cells and their cytokine profiles. Future research will be necessary to elucidate the exact nature of neuropeptide signaling in IBD pathogenesis. As evidence mounts that neuropeptides are implicated in immune cell dysregulation, therapies targeting these neuropeptides may be called upon to regulate immune inflammatory pathways in IBD. Indeed, preclinical studies have already shown the efficacy of certain neuropeptide inhibitors in ameliorating colitis phenotypes. In colitis animal models, the neurotensin receptor inhibitor SR-48,692 was able to suppress the induced colonic secretion, mucosal permeability, and histologic changes associated with C. difficile toxin Ainduced colitis (Castagliuolo et al. 1999 ). In addition, VIP antagonists were similarly able to reduce colitis in animal models. DSS colitis induced C57Bl6 mice treated with VIPHyb, a broad spectrum VIP antagonist which inhibits mainly VPAC1, but also VPAC2 and PAC1 receptors, or with PG 97-269 which selective inhibits only VPAC1 receptors, were found to have significantly reduced inflammatory parameters of colitis and decreased levels of pro-inflammatory cytokines such as IL-1, TNF-α, and IL-6 (Vu et al. 2014) . Further studies are needed to better understand the nature of neuropeptide signaling in IBD. Animal models of colitis, neuropeptide knockout animals, and neuropeptide antagonists will be critical to this process. It is foreseeable that novel neuropeptide antagonists and possibly antisense molecules targeting specific neuropeptides might be developed as future IBD therapies.
